Research progress on tumor markers in primary hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-2015.2024.01.014

Abstract

Abstract:

Liver cancer is a major cause of cancer burden in the world. In recent decades, the incidence rate of many countries has increased. The pathological type of liver cancer is mainly hepatocellular carcinoma (HCC), which is the cause of diagnosis and death of most liver cancers. This article is mainly about the carcinogenic mechanism of primary HCC tumor markers alpha-fetoprotein (AFP), abnormal prothrombin (DCP), alpha-fetoprotein heterogene-3 ratio (AFP-L3%), circulating DNA (cfDNA/ctDNA, circulating free DNA), Golgi protein 73 (GP-73), osteopontin (OPN), phosphatidylinositol protein polysaccharide 3 (glycan-3), detection of therapeutic efficacy, related therapeutic targets, survival rate, recurrence rate and related research progress of GALAD model after resection.

Key words: Hepatocellular carcinoma, Tumor markers

Fei Wan, Yongjun Ren. Research progress on tumor markers in primary hepatocellular carcinoma[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(01): 77-81.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.01.014

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I01/77

References 63

[1]	McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma[J]. Hepatology, 2021, 73 Suppl 1(Suppl 1): 4-13.
[2]	Zheng Y, Zhu M, Li M. Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2020, 146(10): 2439-2446.
[3]	中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J/OL]. 肿瘤综合治疗电子杂志, 2022, 8(2): 16-53.
[4]	中华人民共和国国家卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 传染病信息, 2017, 30(3): 111-127.
[5]	European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943.
[6]	Wong RJ, Ahmed A, Gish RG. Elevated alpha-fetoprotein: differential diagnosis-hepatocellular carcinoma and other disorders [J]. Clin Liver Dis, 2015, 19(2): 309-23.
[7]	Reig M, Forner A, Rimola J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76(3): 681-693.
[8]	Li W, Liu K, Chen Y, Zhu M, et al. Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance[J]. Curr Med Chem, 2021, 28(6): 1126-1142.
[9]	Guo C, Liang H, Yuan W, et al. Analysis on the value of soluble intercellular adhesion molecule-1(sICAM-1), alpha fetoprotein (AFP), and aspartate aminotransferase/platelet ratio index(APRI) in predicting the prognostic survival of patients with primary liver cancer after radiofrequency ablation[J]. Ann Palliat Med, 2021, 10(4): 4760-4767.
[10]	龚培贤, 孙涛, 刘金玮, 等. 肝细胞癌根治性切除术患者术前血清AFP、VEGF水平及肿瘤组织Ki-67表达水平与早期复发的关系[J]. 山东医药, 2022, 62(15): 28-32.
[11]	Wang X, Wang Q. Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity[J]. Can J Gastroenterol Hepatol, 2018, 2018: 9049252.
[12]	Yang X, Chen L, Liang Y, et al. Knockdown of alpha-fetoprotein expression inhibits HepG2 cell growth and induces apoptosis[J]. J Cancer Res Ther, 2018, 14(Supplement): S634-S643.
[13]	Zhu W, Peng Y, Wang L, et al. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy[J]. Hepatology, 2018, 68(2): 574-589.
[14]	Li H, Liu Y, Jiang W, et al. Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma[J]. BMC Cancer, 2021, 21(1): 318.
[15]	Tang W, Miki K, Kokudo N, et al. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma[J]. Int J Oncol, 2003, 22(5): 969-975.
[16]	Suzuki M, Shiraha H, Fujikawa T, et al. Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma[J]. J Biol Chem, 2005, 280(8): 6409-6415.
[17]	Yue P, Gao ZH, Xue X, et al. Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway[J]. Eur J Cancer, 2011, 47(7): 1115-1124.
[18]	Gao FJ, Cui SX, Chen MH, et al. Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells[J]. Life Sci, 2008, 83(23/24): 815-820.
[19]	Cui SX, Yu XF, Qu XJ. Roles and Signaling Pathways of Des-γ-Carboxyprothrombin in the Progression of Hepatocellular Carcinoma[J]. Cancer Invest, 2016, 34(9): 459-464.
[20]	Durazo FA, Blatt LM, Corey WG, et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2008, 23(10): 1541-1548.
[21]	Bertino G, Ardiri A, Malaguarnera M, et al. Hepatocellualar carcinoma serum markers[J]. Semin Oncol, 2012, 39: 410-433.
[22]	Debes JD, Romagnoli PA, Prieto J, et al. Serum biomarkers for the prediction of hepatocellular carcinoma[J]. Cancers, 2021, 13: 1681.
[23]	Choi JY, Jung SW, Kim HY, et al. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP[J]. World J Gastroenterol, 2013, 19(3): 339-346.
[24]	Harimoto N, Yoshida Y, Kurihara T, et al. Prognostic impact of des-γ-carboxyl prothrombin in living-donor liver transplantation for recurrent hepatocellular carcinoma[J]. Transplant Proc, 2015, 47(3): 703-704.
[25]	Kudo A, Shinoda M, Ariizumi S, et al. Association for Clinical Research on Surgery Group. Des-gamma-carboxy prothrombin affects the survival of HCC patients with marginal liver function and curative treatment: ACRoS1402[J]. J Cancer Res Clin Oncol, 2020, 146(11): 2949-2956.
[26]	Tateishi R, Shiina S, Yoshida H, et al. Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers[J]. Hepatology, 2006, 44(6): 1518-1527.
[27]	Yue P, Gao ZH, Xue X, et al. Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway[J]. Eur J Cancer, 2011, 47(7): 1115-1124.
[28]	Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma[J]. Clin Chim Acta, 2001, 313(1/2): 15-19.
[29]	Taketa K, Okada S, Win N, et al. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar[J]. Acta Med Okayama, 2002, 56: 317-320.
[30]	Khien VV, Mao HV, Chinh TT, et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carci-noma[J]. Int J Biol Markers 2001, 16: 105-111.
[31]	Zhou JM, Wang T, Zhang KH. AFP-L3 for the diagnosis of early hepatocellular carcinoma: A meta-analysis[J]. Medicine(Baltimore), 2021, 100(43): e27673.
[32]	Wang X, Zhang Y, Yang N, et al. Evaluation of the Combined Application of AFP, AFP-L3%, and DCP for Hepatocellular Carcinoma Diagnosis: A Meta-analysis[J]. Biomed Res Int, 2020, 2020: 5087643.
[33]	Lim TS, Kim DY, Han KH, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients[J]. Scand J Gastroenterol, 2016, 51(3): 344-353.
[34]	Singal AG, Tayob N, Mehta A, et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis[J]. Hepatology, 2022, 75(3): 541-549.
[35]	Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Der GALAD-Score, ein AFP-, AFP-L3- und DCP-basierter Diagnosealgorithmus verbessert die Detektionsrate des hepatozellulären Karzinoms im BCLC-Frühstadium signifikant[J]. Z Gastroenterol, 2016, 54(12): 1296-1305.
[36]	Schotten C, Ostertag B, Sowa JP, et al. GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients[J]. Pharmaceuticals(Basel), 2021, 14(8): 735.
[37]	Sachan A, Kushwah S, Duseja A. GALAD Score for HCC Screening and Surveillance[J]. Clin Gastroenterol Hepatol, 2023, 21(2): 556-557.
[38]	Yang JD, Addissie BD, Mara KC, et al. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(3): 531-538.
[39]	Ray SK, Mukherjee S. Cell Free DNA as an Evolving Liquid Biopsy Biomarker for Initial Diagnosis and Therapeutic Nursing in Cancer- An Evolving Aspect in Medical Biotechnology[J]. Curr Pharm Biotechnol, 2022, 23(1): 112-122.
[40]	Udomruk S, Orrapin S, Pruksakorn D, et al. Size distribution of cell-free DNA in oncology[J]. Crit Rev Oncol Hematol, 2021, 166: 103455.
[41]	Wu X, Li J, Gassa A, et al. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma[J]. Int J Biol Sci, 2020, 16(9): 1551-1562.
[42]	Howell J, Atkinson SR, Pinato DJ, et al. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma[J]. Eur J Cancer, 2019, 116: 56-66.
[43]	Matsumae T, Kodama T, Myojin Y, et al. Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy[J]. Cancers(Basel), 2022, 14(14): 3367.
[44]	Alunni-Fabbroni M, Rönsch K, Huber T, et al. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial[J]. J Transl Med, 2019, 17(1): 328.
[45]	Oh CR, Kong SY, Im HS, et al. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib[J]. BMC Cancer, 2019, 19(1): 292.
[46]	Wang Y, Zhou K, Wang X, et al. Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments[J]. Cancer Sci, 2021, 112(11): 4772-4784.
[47]	Mao Y, Yang H, Xu H, et al. Golgi protein 73(GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12): 1687-1693.
[48]	Zhang YL, Zhang YC, Han W, et al. Effect of GP73 silencing on proliferation and apoptosis in hepatocellular cancer[J]. World J Gastroenterol, 2014, 20(32): 11287-11296.
[49]	Zhao J, Xu T, Wang F, Cai W, Chen L. miR-493-5p suppresses hepatocellular carcinoma cell proliferation through targeting GP73[J]. Biomed Pharmacother, 2017, 90: 744-751.
[50]	Chen X, Wang Y, Tao J, et al. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice[J]. Gastroenterology, 2015, 149(3): 741-52. e14.
[51]	Wang C, Gao D, Guo K, et al. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model[J]. BMC Cancer, 2012, 12: 166.
[52]	Uede T. Osteopontin, intrinsic tissue regulator of intractable inflammatory diseases[J]. Pathol Int, 2011, 61(5): 265-280.
[53]	Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma[J]. Cancer, 2003, 98(1): 119-127.
[54]	Liang KH, Yeh CT. OPN sesame[J]. Hepatobiliary Surg Nutr, 2014, 3(3): 112-114.
[55]	Lee YJ, Jang BK. Can combination of osteopontin and peritumor-infiltrating macrophages be a prognostic marker of early-stage hepatocellular carcinoma?[J]. Hepatobiliary Surg Nutr, 2014, 3(2): 57-59.
[56]	Zhou C, Zhou HJ, Zhang XF, et al. Postoperative serum osteopontin level is a novel monitor for treatment response and tumor recurrence after resection of hepatitis B-related hepatocellular carcinoma[J]. Ann Surg Oncol, 2013, 20(3): 929-937.
[57]	Zhu Y, Yang J, Xu D, et al. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade[J]. Gut, 2019, 68(9): 1653-1666.
[58]	Zhu Y, Gao XM, Yang J, et al. C-C chemokine receptor type 1 mediates osteopontin-promoted metastasis in hepatocellular carcinoma[J]. Cancer Sci, 2018, 109(3): 710-723.
[59]	Chen RX, Xia YH, Xue TC, et al. Transcription factor c-Myb promotes the invasion of hepatocellular carcinoma cells via increasing osteopontin expression[J]. J Exp Clin Cancer Res, 2010, 29(1): 172.
[60]	Chen RX, Xia YH, Xue TC, et al. Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. Oncol Rep, 2011, 25(3): 803-808.
[61]	Iglesias BV, Centeno G, Pascuccelli H, et al. Expression pattern of glypican-3(GPC3) during human embryonic and fetal development[J]. Histol Histopathol, 2008, 23(11): 1333-1340.
[62]	Capurro M, Wanless IR, Sherman M, et al. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma[J]. Gastroenterology, 2003, 125(1): 89-97.
[63]	Zhou F, Shang W, Yu X, et al. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment[J]. Med Res Rev, 2018, 38(2): 741-767.

Please choose a citation manager

Content to export